

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform its shareholders and potential investors that, in the face of a complex and ever-changing external environment, in 2023, through adhering to the business-focused strategy and with the primary goal of promoting sustainable business growth, the Group enhanced its operational efficiency in a sustained and in-depth manner. Leveraging on the comprehensive layout of multi-surgical specialties, excellent product performance and industry-leading commercialisation capabilities, the Group has made breakthroughs in the domestic commercialisation and global expansion of a number of its listed products. The Board expects that the revenue of the Company for the year ended 31 December 2023 (the “**Period**”) will achieve a year-on-year growth of over 350% as compared to that for the year ended 31 December 2022, which is mainly attributable to the continuous growth in sales revenue from the full-scale commercialisation of the Group’s products, namely Toumai Laparoscopic Surgical Robot (the “**Toumai**”), SkyWalker Joint Replacement Surgical Robot and DFVision 3D Electronic Laparoscope.

The Board expects that the Company will record a net loss of not more than RMB1,050 million for the year ended 31 December 2023 (for the year ended 31 December 2022: RMB1,146 million). The decrease in the expected net loss is mainly attributable to (i) an increase in gross profit driven by the growth of revenue; and (ii) a decrease in research and development (“**R&D**”) expenses with the enhancement of R&D efficiency through focusing on core R&D projects. However, the impact of the above factors were partially offset by an increase in selling expenses as a result of carrying out commercial activities vigorously for the promotion of a number of the Group’s listed products, additional one-off adjustment expenses arising from business focus (such as expenses related to the adjustment of leased premises), provision for impairment of inventories made due to impairment indications of certain inventories, and losses on changes in fair value of overseas investments held by the Group based on assessment during the Period.

To date, the Group has demonstrated good commercialisation momentum and globalisation progress, in particular, the domestic bidding process has accelerated significantly since the approval of Toumai multi-discipline registration in October 2023, and the Group has also successfully secured overseas orders, which continued to consolidate the Company's leading position among domestic brands; meanwhile, the various cost reduction and efficiency improvement measures effectively implemented during the Period are expected to lay a good foundation for improving the Group's subsequent profitability. In the future, the Group will strive to promote the continuous growth of domestic and international sales revenue of diversified product portfolio brought by extensive layout, maintain the Company's innovation ability and rapid transformation ability of R&D achievements, further explore, optimise and improve the operational efficiency, and create greater value for shareholders of the Company and the industry.

As at the date of this announcement, the Company is still in the process of preparing and completing its annual results for the year ended 31 December 2023. The information contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant information available to the Board as of the date of this announcement, which has not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Board, and may be subject to adjustments. The audited annual results announcement of the Company for the year ended 31 December 2023 will be published on or before 31 March 2024. Shareholders of the Company and potential investors are advised to read carefully the audited annual results announcement upon publication.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 5 March 2024

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.